This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Harousseau JL, Attal M, Avet-Loiseau H . The role of complete response in multiple myeloma. Blood 2009; 114: 3139–3146.
Giralt S, Qazilbash M . High-dose therapy for multiple myeloma—getting beyond high-dose melphalan. Haematologica 2007; 92: 2.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
Mitchell BS . The proteasome—an emerging therapeutic target in cancer. N Engl J Med 2003; 348: 2597–2598.
Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380.
Kaufman JL, Lonial S, Sinha R, Torre C, Langston AA, Lechowitz MJ et al. A randomized phase I trial of melphalan and bortezomib for autologous transplant in myeloma. Clin Lymphoma Myeloma 2009; 9 (S2): 560 (abstract no. 364).
Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115: 32–37.
Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385–390.
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Thompson, P., Prince, H., Seymour, J. et al. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 46, 764–765 (2011). https://doi.org/10.1038/bmt.2010.180
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.180
This article is cited by
-
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma
Bone Marrow Transplantation (2014)
-
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
International Journal of Hematology (2013)
-
New developments in conditioning regimens before auto-SCT in multiple myeloma
Bone Marrow Transplantation (2011)